Mayne Pharma
Mr David Petrie is an accomplished M&A executive with over 30 years of advisory experience in public and private mergers and acquisitions, capital management and debt and equity raisings. He is currently Principal at Stratford Advisory Group, an independent corporate and financial advisory firm. Previously, he spent 23 years at Merrill Lynch/Bank of America including Managing Director and Head of Investment Banking Melbourne. He has worked on more than 100 transactions across a range of market sectors including healthcare. Mr Petrie has a Bachelor of Commerce (Honours) and Bachelor of Law (Honours) from the University of Melbourne. He has been a CPA for 30 years and is admitted as Barrister and Solicitor of the Supreme Court of Victoria.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Mayne Pharma
1 followers
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing branded and generic pharmaceuticals. It operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI). The GPD segment is engaged in the manufacture and distribution of generic pharmaceutical products in the United States. The SBD segment markets and distributes specialty branded pharmaceutical products in the United States. The MCS segment is engaged in the provision of contract analytical and pharmaceutical development services to third-party customers in the United States. The MPI segment is engaged in Australian manufacture and sale of branded and generic pharmaceutical product globally and provision of contract manufacturing services to third-party customers within Australia.